Shares of pharmaceuticals giant Wockhardt Ltd slipped as much as 14 per cent after the company revealed that American health regulator had imposed restrictions on import of medicines produced by its Chikalthana manufacturing facilities.

In a filing to the Bombay Stock Exchange (BSE) on Wednesday, Wockhardt said it had received a warning letter from the U. S. Food & Drug Administration (USFDA) for its manufacturing plant situated at L1, Chikalthana in Aurangabad.

In the filing, the company stated, "USFDA has also posted on its website an import alert on the manufacturing unit at L1, Chikalthana, Aurangabad. USFDA has however, excluded five products from import alert."

The facility in question produces medicines like Metoprolol XR, which is used to treat blood pressure.

In the afternoon trade, Wockhardt shares were trading at Rs 428.45 apiece, at a loss of 9.23 per cent from their previous close.

Wockhardt has assured that it had already initiated steps to address the U. S. health regulator's concerns, adding that it would make all efforts to resolve the issue at the earliest.

It is not the first time that a foreign health regulator has issued a warning against the company's medicines. In May, the USFDA slapped an import alert on Wockhardt's Waluj plant, which produces solid dosages and injectables. Later in October, British health regulator imposed an import ban in medicines produced at the company's Kadaiya plant.